Show simple item record

dc.contributor.authorVarghese, AM
dc.contributor.authorHoward, DR
dc.contributor.authorPocock, C
dc.contributor.authorRawstron, AC
dc.contributor.authorFollows, G
dc.contributor.authorMcCarthy, H
dc.contributor.authorDearden, C
dc.contributor.authorFegan, C
dc.contributor.authorMilligan, D
dc.contributor.authorSmith, AF
dc.contributor.authorGregory, W
dc.contributor.authorHillmen, P
dc.date.accessioned2018-03-02T14:59:03Z
dc.date.issued2017-02
dc.identifier.citationBritish Journal of Haematology, 2017, 176 (4), pp. 573 - 582
dc.identifier.issn0007-1048
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1519
dc.identifier.doi10.1111/bjh.14342
dc.format.extent573 - 582
dc.languageeng
dc.language.isoeng
dc.publisherWiley
dc.titleEradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/bjh.14342
rioxxterms.licenseref.startdate2017-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish Journal of Haematology
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume176
pubs.embargo.termsNot known
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record